Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colistin Dosing in Pediatric Cancer with Gram-Negative Infections
NCT03397914Phase 4Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2017
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of colistimethate sodium in Gram-negative bacterial infection, sepsis, sponsored by National Cancer Institute. Started Jan 2017; status: completed.
02
Drugs
colistimethate sodium
03
Conditions
Gram-negative bacterial infectionsepsis
Beyond the preview
Go deeper on NCT03397914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03397914.